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Abstract 
 
Solid tumours are constituted of tumour cells, healthy cells recruited from the host 
tissues and soluble factors released by both these cell types. The present 
investigation examines the capacity of co-cultures between the HCEC colon epithelial 
cells and the HCT-116 colorectal cancer cells (mimicking the primary site of tumour 
growth) and between IHH hepatocytes and the HCT-116 colorectal cancer cells 
(metastatic site) to influence the effects of NAMI-A (imidazolium trans-
imidazoledimethylsulphoxidetetrachloro ruthenate) on the tumour cells themselves. 
The growth of HCT-116 cells is significantly influenced when the cancer cells are 
sown on a monolayer of HCEC. The release of soluble factors by the healthy cells 
promotes, in HCT-116 colorectal cancer cells, the transcription of genes involved in 
growth, invasion and migration. NAMI-A is not cytotoxic to HCT-116 cells grown on 
plastics or co-cultured with HCEC or IHH cells, and maintains its ability to control the 
cell pseudo-metastatic ability, mimicked by the migration in the scratch test. The 
effects of NAMI-A on HCT-116 migration are supported by its inhibition of the 
transcription of the ABL-2, ATF-3 and RND-1 genes. In conclusion the study 
highlights the need of test systems more complex than a single cancer cell culture to 
study an anticancer drug in vitro and reinforces the hypothesis that NAMI-A targets 
the ability of the cancer cell to interact with the tumour microenvironment and with the 
signals that support its metastatic ability. 
 
Key words: colorectal cancer, microenvironment, ruthenium, metastasis. 
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1. INTRODUCTION 
 
In the last 15 years, the search for anti-tumour drugs has been largely shifted from 
direct targeting of the cell replicative mechanism to the overexpressed molecules to 
which is attributed the responsibility for the tumour malignancy [1]. Similarly, the 
research for new chemical entities has been oriented to match with this new fashion 
with a series of novel compounds to which it has often been attributed the adjective 
of “biological” drugs because of their similitude with endogenous compounds [2]. This 
strategy of anti-tumour chemotherapy has produced monoclonal antibodies against 
receptors overexpressed by cancer cells and small molecules, mainly, but not only, 
inhibitors of tyrosine kinases representing the pathways responsible for the 
malignancy of the tumour cells [3-5]. This new approach accounts for certain 
improvements of the anticancer chemotherapy [6], but the initial enthusiasm has 
been reduced because of the onset of tumour resistance and because of the tumour 
cell heterogeneity with often only few cells in a tumour that have responded to 
therapy [7-10]. 
In the area of cancer chemotherapy, the role of metal-based drugs is still occupied by 
the few platinum-based drugs that have been worldwide (cisplatin, carboplatin and 
oxaliplatin) or locally (nedaplatin, lobaplatin and heptaplatin) approved for use in man 
[11]. These drugs, although acting on tumour cells with the so-called “conventional 
mechanism”, because their efficacy is ascribed to their ability to bind to DNA [12,13], 
still offer a good reference for the pharmacological approach to numerous 
malignancies and are included in the therapeutic schemes of some important 
neoplasms such as non-small cell lung cancer (NSCLC) [14]. Recent studies open 
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the hypothesis that also the activity of platinum drugs may depend on the 
characteristic pathways of the tumour cells, and in this way it can be explained the 
relative sensitivity of certain tumours [15-21]. However, tumour growth in the primary 
and metastatic sites depends also from the relationships that cancer cells hire with 
the healthy cells surrounding the tumour mass. The presence of a number of healthy 
cells in the tumour mass is believed to help the growth of the tumour [22,23], and is 
suspected it can interfere with the activity of the anti-tumour drugs [24-27]. This 
interference may be even greater with the “targeted drugs” for which any external 
influence on the expression/activity of the pathways of malignancy may represent an 
obstacle to their efficacy. 
Among the metal-based drugs, the imidazolium trans-imidazoledimethylsulphoxide-
tetrachloro ruthenate (NAMI-A) has shown important differences of the mechanism of 
anti-tumour action. It shows only poor capacity to bind to DNA [28], also because of 
its poor ability to get into the cells [29] while causing a pronounced reduction of the 
metastatic capacity of the tumours [30-32]. The selectivity of NAMI-A for the tumour 
metastases has been attributed to its ability to control the angiogenic potential of the 
tumour [33,34], and to control the integrin-dependent interaction of the tumour with its 
growth microenvironment [35-37]. 
With the present investigation we have studied the capacity of the healthy cells 
surrounding the colorectal cancer cells, in the primary site or in the liver metastases, 
to influence the effects of NAMI-A on the tumour cells themselves. The study has 
been therefore carried out with co-cultures mimicking the primary site of tumour 
growth (co-culture between the HCEC epithelial cells and the HCT-116 colorectal 
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cancer cells) and of the liver metastatic site (co-culture between the IHH hepatocytes 
and the HCT-116 colorectal cancer cells). 
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2.  MATERIALS AND METHODS 
 
2.1 CELL CULTURES 
The human adenocarcinoma colon cancer cell line HCT-116 was kindly supplied by 
the group of Dr. C. Gaiddon, University of Strasbourg, France. The cell line was 
cultured in Dulbecco’s Modified Eagle Medium (DMEM, Euroclone Ltd., UK) 
supplemented with 10% foetal bovine serum (FBS, Gibco-Invitrogen Corp., UK), 2 
mM L-glutamine (Euroclone), 100 IU/ml and 100 g/ml streptomycin solution 
(Euroclone). 
The human immortalized hepatocytes cell line IHH was kindly supplied by the group 
of Prof. C. Tiribelli, CSF, University of Trieste, Italy. The cell line was cultured in 1:1 
DMEM/HAM’s F12 medium supplemented with 10% FBS, 2 mM L-glutamine, 100 
IU/ml penicillin and 100 g/ml streptomycin solution, 10-4 M dexamethasone (Sigma-
Aldrich, MO, USA), 10-8 M pancreatic bovine insulin (Sigma-Aldrich), 1 M Hepes 
Buffer (Sigma-Aldrich). 
The human colon epithelial cell line HCEC was kindly supplied by Dr. P. Steinberg, 
Institute for Food Toxicology and Analytical Chemistry, University of Veterinary 
Medicine Hannover, Germany. The cell line was cultured in DMEM supplemented 
with 10% FBS, 2 mM L-glutamine, 100 IU/ml penicillin and 100 g/ml streptomycin 
solution, 1 mM sodium pyruvate (Sigma-Aldrich), 0.5 mM ethanolamine (Sigma-
Aldrich), 0.5 M o-phosphoethanolamine (Sigma-Aldrich), 0.3% bovine serum 
albumin (BSA, Sigma-Aldrich), 20 mM Hepes Buffer (Sigma-Aldrich). 
The cell lines were grown in an incubator with 5% CO2 and 100% relative humidity at 
37°C. Once 90% of confluence was reached, the cell lines were detached with 
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trypsin/EDTA solution (0.05% trypsin, 0.02% EDTA in Phosphate Buffered Saline 
PBS, Sigma-Aldrich). Cell viability was determined by the trypan blue dye exclusion 
test. 
 
2.2 IHH AND HCEC CONDITIONED MEDIUM PREPARATION 
The IHH conditioned medium (IHH-CM) was obtained culturing IHH cells at 
approximately 70-80% of confluence in their standard medium for 24 h, afterwards it 
was collected and stored at -20°C until use. The same procedure was followed to 
prepare the HCEC conditioned medium (HCEC-CM). 
 
2.3 CO-CULTURE MODEL 
The co-cultures have been set up by growing the HCT-116 colorectal cancer cells on 
a monolayer of epithelial colon cells HCEC, or of hepatocytes IHH. With a view to set 
up a co-culture with the three cell line together, in this experimental setting cells were 
grown in the complete medium formulated for the IHH cell line, the most demanding 
cells among the three cell lines used. In each co-culture the two cell lines were 
stained with different fluorescent dyes. The two cell lines that must constitute the 
layer on which to grow the HCT-116 colorectal cancer cells, i.e. HCEC and IHH, were 
stained with Calcein AM (Molecular Probes, Invitrogen, Paisley, UK). Briefly, cells 
were detached, sown in complete medium in a 96-well plate (1x104/well) and left 
adhere for 24 h at 37°C and 5% CO2. Then, the culture medium was substituted with 
a solution of 15 M Calcein AM, dissolved in complete medium, for 30 min at 37°C 
and 5% CO2. After a careful wash fresh culture medium was added. Meanwhile, 
HCT-116 cells were detached, re-suspended in PBS containing Fast DiI (1,1’-
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dilinoleyl-3,3,3’,3’-tetramethylindocarbocyanine perchlorate, Molecular Probes) for 15 
min at 37°C and 5% CO2. At the end of the incubation time, cell suspension was 
centrifuged, carefully washed to eliminate the excess of the dye, re-suspended in 
complete medium, and sown (1x104/well) over the monolayer of HCEC or of IHH 
cells. After 24 h cells were treated with 100 M NAMI-A, diluted in complete medium 
starting from a 10-2 M mother solution in sterile water, for 72 h at 37°C and 5% CO2. 
At the end, the medium containing the ruthenium compound was removed, the cells 
carefully washed with PBS, and 100 l of fresh PBS added to each well. 
Fluorescence was then read with a fluorimeter FluoroCount Packard Bell at ex = 
485 nm and em = 520 nm for Calcein A , ex = 544 nm and em = 580 nm for Fast 
DiI. 
 
2.4 GENE EXPRESSION BY qRT-PCR 
The differential expression of ABL-2, ATF-3, NR4A1, RND-1, SIK-1, and STK-11 
genes in HCT-116 cells grown in HCEC-CM and in IHH-CM was analysed by real 
time reverse-transcription PCR (qRT-PCR). Cells (4x105) were sown in 25 cm2 
flasks, on reaching 90% of confluence, cells were exposed for 24 h to HCEC-CM or 
to IHH-CM, as controls the same media, but non conditioned, were used (HCEC-M 
and IHH-M). The method was similarly applied to measure the expression of the 
same genes after treatment of HCT-116 cells with NAMI-A. In this case, cells at 90% 
of confluence were treated with 10 M NAMI-A, dissolved in complete medium, for 1 
h or for 24 h.  
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For both experimental settings at the end of the incubation time cells were detached 
and re-suspended in TRIzol (Invitrogen). Total RNA was isolated following the 
phenol/chloroform extraction procedure. RNA was reverse-transcribed using 
qScript cDNA Synthesis Kit (Quanta Biosciences, Gaithersburg, MD, USA) 
according to the manufacturer’s protocol. Real time PCR analyses were conducted 
on a CFX system mounted on a C1000 thermal cycler (Bio-Rad, Hercules, CA, USA) 
using SsoAdvanced SYBR Green Supermix (Bio-Rad) following manufacturer’s 
protocol. The following thermal profile was used: an initial 30 sec denaturation step at 
95°C, followed by 40 cycles at 95°C for 15 sec and at 55°C for 30 sec. Amplification 
products were analysed using a 65°C/95°C melting curve. The MIT Prime3 online 
protocol was used to design the primer sequences reported in Table 1. Primers were 
designed to avoid the non-specific amplification of other human transcripts by an in 
silico analysis via BLASTn against the annotated human genome (Ensambl release 
68) [38]. Primer specificity was further assessed by a melting curve analysis of RT-
PCR products. Primers were purchased from Invitrogen. Gene expression levels 
were calculated using the comparative Ct method and normalized using the RPL5 
gene as the internal control [39]. The results are provided as the mean and standard 
deviation of three technical replicates. 
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Table 1. Primers used for qRT-PCR 
Gene Forward Reverse 
ABL-2 5’-CTGTAATGACGACGGTGGTG-3’ 5’-ACTGGCTGTGGGTTTACCTG-3’ 
ATF-3 5’-GTGGTACCCAGGCTTTAGCA-3’ 5’-ACAGTAGCCAGCGTCCTTGT-3’ 
NR4A1 5’-AGTGCAGAAAAACGCCAAGT-3’ 5’-CGGACAACTTCCTTCACCAT-3’ 
RND-1 5’AGCGACTCGGATGCAGTATT-3’ 5’-GTCTGTCTTGCAGCCAATGA-3’ 
SIK-1 5’-TCCCCTGAAATCAAAACCTG-3’ 5’-TGAAGTCACCTCTGCCCTCT-3’ 
STK-11 5’-GAGCTGATGTCGGTGGGTAT-3’ 5’-CTTCACCTTGCCGTAAGAGC-3’ 
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2.5 WOUND HEALING ASSAY 
The assay was conducted according to the protocol described by Liang et al. [40]. 
Briefly, HCT-116 cells were sown in complete medium in 24-well plates (4x104 
cells/well) and grown at 37°C and 5% CO2 until 90% of confluence. Cells were then 
serum starved and incubated for 24 h in a medium (HCT-116-M-FBS+BSA) 
containing 0.1% Bovine Serum Albumin (BSA, Sigma-Aldrich). The next day cells 
were treated with the medium conditioned by the hepatocytes IHH (IHH-CM), with 
vascular endothelial growth factor (VEGF 0.9 ng/ml, 1.8 ng/ml, 3.6 ng/ml, Merck 
Millipore, Temecula, CA, USA) and/or with monocyte chemoattractant protein 1 
(MCP-1 0.07 ng/ml, 0.7 ng/ml, 7 ng/ml, Invitrogen, Life Technologies). Solutions of 
VEGF and MCP-1 were prepared in HCT-116-M-FBS+BSA starting from a mother 
solution 9 g/ml VEGF in 0.1% trifluoroacetic acid, and 25 g/ml MCP-1 in sterile 
water. The effects of the ruthenium compound were studied by combining IHH-CM, 
VEGF and MCP-1 treatment with a contemporary treatment with 1, 10 and 100 M 
NAMI-A. Using a yellow pipette tip a straight scratch was made in the cell monolayer. 
Cells were then incubated for 48 h at 37°C and 5% CO2. Treatment solutions were 
removed and cells fixed with 1.1% glutaraldeyde for 15 min. After a careful wash the 
plates were air-died and cells observed at light microscopy equipped with a Leica 
DC300 acquisition system. 
 
2.6 TARGETED SECRETOME ANALYSIS OF THE IHH-CM PROFILING BY MULTIPLEXED 
IMMUNOASSAY 
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The targeted quantitative analysis of secreted cytokines and chemokines in IHH-CM 
was performed by using the Bio-Plex multiplex system (Bio-Rad, Milan, Italy) based 
on xMAP technology that makes use of magnetic beads coated with specific 
antibodies raised against target analytes. Microspheres are internally labeled with red 
and infrared fluorophores. Each bead is bound to a specific antibody, thus allowing 
the simultaneous detection of multiple analytes within one sample. Following reaction 
of coupled beads with target analytes within IHH-CM, a biotinylated antibody is 
added for the detection, which is then finalized by adding phycoerytrin-conjugated 
streptavidin. All steps were performed according to manufacturer's instructions. IHH-
CM was analyzed with this technology determining simultaneously the concentration 
of interleukin IL-1, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-
13, IL-15, IL-17A, IP10, Eotaxin, Granulocyte-colony stimulating factor (G-CSF), 
Granulocyte-macrophage colony stimulating factor (GM-CSF), Interferon gamma 
(IFN)γ, Monocyte chemoattractant protein 1 (MCP-1/CCL2), Macrophage 
inflammatory protein 1-alpha and beta (MIP-1α and MIP-1β), RANTES, Tumor 
necrosis factor alpha (TNFα), Platelet-derived growth factor-BB (PDGF-BB), Vascular 
endothelial growth factor (VEGF), Basic fibroblast growth factor (bFGF). Data were 
acquired using a Bio-Plex MAGPIX Multiplex Reader system equipped with a Bio-
Plex Manager software v 6.1 (BioRad). All washing steps were performed on the Bio-
Plex magnetic wash station (BioRad). Measurements were performed on IHH-CM 
samples (50 µL) using the Bio-Plex Pro Human Cytokine 27-plex assay kit (Cat. N° 
M50-0KCAF0Y, BioRad) according to the manufacturer’s protocol. An aliquot of 
DMEM/HAM’s F12 medium (50 µL) was also analysed as negative control. Standard 
curves optimization and the calculation of analyte concentrations were performed by 
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using the Bio-Plex Manager software. Data were expressed as mean +/- standard 
deviation (SD). A two-tailed t-test was used to test the significance between the IHH-
CM and the negative control medium by using the GraphPad Prism software v 5.0 
(La Jolla, CA USA). Expression data were also imported into the excel software for 
further analyses. 
 
2.7 STATISTICAL ANALYSIS 
Results are processed using InstatGraph3 software and presented as mean  S.D.. 
The group means are compared using a two-Way Analysis of Variance (ANOVA) 
followed by t-test, or Tukey-Kramer post-test and are considered significant when 
p<0.05. 
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3. RESULTS 
 
3.1 INFLUENCE OF THE CO-CULTURE WITH EPITHELIAL COLON CELLS (HCEC) AND WITH 
HEPATOCYTES (IHH) ON THE HCT-116 CELL RESPONSE TO NAMI-A 
HCT-116 colorectal cancer cells, cultured on a monolayer of epithelial colon cells 
(HCEC), gain a significant growth advantage compared to the same cells grown 
directly on plastics (p<0.01) (Figure 1). Conversely, this effect is not noticed if the 
monolayer beneath HCT-116 is made up of IHH hepatocytes. The treatment of HCT-
116 colorectal cells grown on plastics with 100 M NAMI-A does not cause a 
reduction of cell viability, whereas the response of HCT-116 cells to NAMI-A, in a 
condition of co-culture, depends on the nature of the second cell line. The presence 
of the IHH hepatocytes confers to the HCT-116 cells a more marked resistance to the 
ruthenium compound, giving a significant growth advantage compared to the same 
cells treated with NAMI-A on plastics (p<0.05). The co-culture with HCEC epithelial 
colon cells does not affect the HCT-116 cell response to NAMI-A (Figure 1). 
 
3.2 NAMI-A TREATMENT CONTRASTS THE INCREASE OF HCT-116 GENE EXPRESSION 
INDUCED BY HCEC-CM AND IHH-CM 
The exposure of HCT-116 cells to the medium conditioned with either the epithelial 
colon cells (HCEC-CM) and the hepatocytes (IHH-CM) increases the expression of 
genes involved in processes of invasion and metastasis, and cellular growth in 
comparison to the same cells kept in the respective non-conditioned media (Figure 
2A). HCEC-CM causes a meaningful increase of all the tested genes, particularly 
relevant for RND-1 and SIK-1. The soluble factors secreted by IHH hepatocytes in 
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the IHH-CM lead to a similar increase of gene expression, although quantitatively 
less marked than that induced with the HCEC-CM. Contrariwise, NAMI-A treatment 
leaves unchanged or even reduces the expression of the same genes (Figure 2B). 
The reduction is more marked and significant after a prolonged treatment of 24 h of 
the cells with the ruthenium compound. 
 
3.3 NAMI-A PARTIALLY SUPPRESSES HCT-116 CELL MIGRATION STIMULATED BY THE IHH-
CM 
The soluble factors secreted in the medium by the IHH hepatocytes induce the HCT-
116 cells to migrate from the edge of the wound and to partially cover the artificially 
drawn groove (Figure 3, right picture). In the same time frame (48 h) the control cells 
exposed to the non-conditioned IHH medium (Figure 3 middle panel) show a modest 
migration in comparison to the control at time=0 (Figure 3, left panel), immediately 
after having drawn the furrow. 
The treatment of HCT-116 cells with 1 and 10 M NAMI-A slowed-dawn the 
migration of colorectal cancer cells grown with the IHH medium (Figure 4, left 
panels). NAMI-  is less effective if cell migration is stimulated with the same medium 
conditioned by the hepatocytes (IHH-CM) (Figure 4, right panels). Interestingly, in 
this latter case, NAMI-A is more active at the lower dose tested (1 M). 
 
3.4 THE COMPOSITION OF THE IHH SECRETOME 
To investigate the profile of cytokines and growth factors secreted by the IHH 
hepatocytes, a multiplexed immunoassay-based platform was used. Unconditioned 
media were in parallel analysed as a reference sample for comparative purposes. 
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We found that several soluble factors, including both pro-inflammatory and anti-
inflammatory cytokines, chemokines and growth factors, are highly enriched in the 
IHH conditioned media (Table 2). In particular, we focused our attention on the MCP-
1 chemokine and the VEGF growth factor for which the highest concentrations are 
measured (700 and 1600 pg/ml, respectively). 
 
3.5 NAMI-A CURBS THE MIGRATION OF HCT-116 CELLS INDUCED BY VEGF AND/OR MCP-1 
The addition of increasing concentrations of VEGF and MCP-1 alone, or of their 
combination, to cultures of HCT-116 colorectal cancer cells increases the migration 
ability of these cells, especially when MCP-1 and VEGF are used at their highest 
concentrations (Figure 5). The treatment of HCT-116 cells with 1 and 100 M NAMI-
A reduces the migration induced by VEGF and MCP-1, either after the use of each 
substance alone or with their simultaneous presence (Figure 6). 
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4. DISCUSSION 
 
The new innovative approaches to cancer chemotherapy, besides the direct targeting 
of the cancer cell, take into consideration also the tumour microenvironment where 
the neoplasm is growing [26,41]. This new view implies a role for the 
microenvironment for either the growth of the tumour and for the response of the 
tumour cells to the anticancer therapies [23,25,27,42]. In short, it might be said that 
tumour cells recruit host cells and soluble factors to help themselves to grow and to 
be protected against chemicals used for their destruction. Then, it is not surprising 
that many targeted therapies are only marginally effective or rapidly become 
ineffective even when they are expected to be highly cytotoxic to cancer cells 
because of the selective targeting of a pathway crucial to cell survival [24,43,44]. 
Recent evidences with the platinum drugs suggest that also the metal-based 
chemicals are sensitive to the microenvironment of tumour growth [45,46]. Platinum 
drugs are the references for the bioinorganic chemistry in the development of novel 
compounds and among these the ruthenium-based drug NAMI-A has shown the 
most innovative pharmacological properties, consisting of the selective targeting of 
metastases [30-32]. The actual knowledge suggests that the targets of NAMI-A are 
cell components such as the cell surface receptors responsible for the processes of 
invasion and migration [35-37].  
The present study adds new information on this peculiar mechanism of action and 
points out that host cells and their components, released in the microenvironment of 
tumour growth, may influence the efficacy of NAMI-A to control cancer invasion and 
migration. 
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The HCT-116 colon carcinoma cells grow faster when they are sown on a monolayer 
of the healthy counterpart HCEC colon epithelial cells, suggesting that the use of 
simple monolayers of cancer cells is only partially representative of cancer growth. 
Similarly, the pharmacological response to drugs tested on simple monolayers or on 
complex environments, constituted of tumour microenvironment cells and their 
soluble factors, gives substantially different results [47-49]. NAMI-A has never shown 
direct cytotoxicity towards cells cultured in vitro and also in the present study its 
cytotoxicity for the HCT-116 cells is null. The same result is obtained when the HCT-
116 cells are grown over a monolayer of healthy colon epithelial cells. When the 
same study is done with the HCT-116 cells grown over a monolayer of healthy 
hepatocytes (mimicking the metastatic site), the cancer cells become even less 
sensitive to the potential cytotoxic effects of NAMI-A. It should be noted that the 
pharmacological effects of NAMI-A on cancer cells in vitro have always been much 
more evident on the invasion and migration processes than on cell viability [50,51], 
and these properties are confirmed also in the present study. IHH hepatocytes 
stimulate the adhesion of HCT-116 cells to fibronectin, an important extracellular 
matrix component of the liver, suggesting that this mechanism could help the 
formation of colorectal cancer liver metastases on which NAMI-A is active [52]. Here 
we show how IHH hepatocytes also stimulate the migration of HTC-116 cells. IHH 
cells release a number of soluble factors in the medium in which they grow, including 
both pro-inflammatory and anti-inflammatory cytokines, chemokines and growth 
factors. Among these factors, the highest concentrations were determined for MCP-1 
and VEGF. Both these factors are known to be involved in cancer growth and 
dissemination [53-55]. Accordingly, we found that both the single and simultaneous 
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addition of VEGF and MCP-1 to cultures of HCT-116 cells stimulates their migration 
ability. Interestingly, we also found that the treatment of HCT-116 cells with NAMI-A 
reduces the migration induced by VEGF and MCP-1, either used alone or in 
combination. These findings open new perspectives for understanding the NAMI-A 
peculiar properties of selective targeting of metastases by affecting invasion and 
dissemination processes mediated by growth factors and chemokines. When the 
whole “secretome” is used to induce HCT-116 cell migration, the effects of NAMI-A 
are significantly reduced, suggesting that the presence of an array of soluble factors 
released by the IHH hepatocytes synergically and negatively influence the anti-
metastatic effects of the ruthenium-based drug. Similarly to past experiences, also in 
this experiment the highest activity of NAMI-A is evident at the lowest dosage tested 
[37]. This concentration-response trend is typical of the “enzyme-substrate” and/or 
“antigen-antibody” interactions and suggests the action of NAMI-A is the result of a 
pharmacological interaction with a specific target (likely an integrin) rather than the 
merely consequence of a non-selective cytotoxicity. 
These results support the role of the microenvironment, including cells and soluble 
factors, in the modulation of the pharmacological response of cancer cells exposed to 
NAMI-A. This modulation partially reduces the efficacy of NAMI-A even though the 
overall effect of the drug is still measurable. Nevertheless, the results of the present 
study stress the role of the type of model, and of its complexity, used to test the 
pharmacological effect of a drug in vitro. The fact that NAMI-A, for which the weak 
effects on cell cultures in vitro are known, is significantly influenced by the tumour 
complexity may suggest why many drugs fail in vivo although they showed good 
activity on simple cancer cell cultures in vitro. 
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The relationship between cancer cells and healthy cells of the microenvironment of 
tumour growth (whether primary or metastatic site) is also supported by the effects of 
the media conditioned by HCEC or by IHH cells on the expression of genes of the 
colorectal cancer cells. The transcription of genes such as ATF-3 and RND-1, 
involved in processes of invasion and metastasis [56-58], and of NR4A1, SIK-1 and 
STK-11, responsible for growth processes [59,60], is significantly induced by the 
conditioned media obtained from cultures of HCEC or IHH cells. Interestingly, HCEC 
conditioned medium stimulates more relevant changes of all the tested genes except 
NR4A1, which expression is more potently induced by IHH conditioned medium. A 
plausible hypothesis about this finding relies on the non-genomic activities of NR4A1. 
In fact, NR4A1 contributes to the proteasomal degradation of -catenin in colon 
cancer cells in vitro and in vivo [61,62]. We could expect that the greater induction of 
NR4A1 expression by the hepatocyte conditioned medium, respect to the medium 
conditioned by HCEC colon epithelial cells, favours the -catenin degradation in the 
liver. The consequences of the -catenin pathway attenuation are a reduction of cell 
migration and an increase of cell adhesion, thus stressing two features crucial for the 
setup and the consolidation of colorectal tumour metastasis. NAMI-A appears to be 
able to completely control the expression of the genes induced by HCEC-CM and 
IHH-CM in the HCT-116 cells with a result qualitatively opposite to that observed with 
the conditioned media. The functional consequences of the activity of NAMI-A in that 
scenario have been investigated in vitro using a device called “Plastic Mouse”, where 
both healthy epithelial cells and hepatocytes simultaneously condition the colorectal 
cancer cells. It is composed of two chambers, connected through a channel 
permitting the circulation of tumour cells. The first chamber is constituted by a 
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monolayer of epithelial colon cells HCEC on which the HCT-116 colorectal cancer 
cells are growing. The second chamber is set up with a monolayer of IHH 
hepatocytes. The two chambers represent the primary tumour and the liver, 
respectively. The movement of fluorescence-labelled HCT-116 colorectal cancer 
cells from one well to the other is followed in static and dynamic conditions (i.e. with a 
dynamic circulation of the medium, heated by resistors, and completed by a 
computer assisted control of gases and medium injections). The results of this study 
indicate that tumour cells migrate from the “primary tumour” to the “liver metastatic 
site”, and that they adhere to the hepatocytes. In the presence of 10 M NAMI-A we 
could measure an increase of HCT-116 colorectal cancer cells remaining on the 
monolayer of HCEC (+53%), a decrease of the number of circulating colorectal 
cancer cells (-43%), and an even more pronounced decrease (-91%) of the number 
of HCT-116 cells adhering onto the monolayer of IHH hepatocytes in the second well 
[data from Callerio Foundation]. These findings correlate with the results of the 
studies of the effects of the treatment of cancer cells in vitro (and in vivo) prior to their 
implant in vivo in syngeneic animals to observe their growth at primary site of 
implant, and the metastasis formation [63,64]. In these studies, the tumour cells 
exposed to the ruthenium-based drug significantly loose the capacity to metastasize 
to the lung after subcutaneous or intramuscular implantation while maintaining their 
ability to grow in the primary site of tumour implantation. This is in good agreement 
with the results of the present paper showing the reduction by NAMI-A of the 
expression of genes related to the metastatic process, such as RND1, ABL-2, and 
ATF3. In addition, they reinforce the hypothesis that NAMI-A has a preferential 
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activity on the metastasis genes, leaving unaffected the tumorigenic genes involved 
in the proliferation of the tumour cells at their primary site of growth. 
In conclusion, the present study highlights the problem of the in vitro evaluation of the 
potential anticancer activity of a new chemical, suggesting the need of the use of 
more complex systems involving more components in addition to the target cancer 
cell. Also the ruthenium-based drug NAMI-A is sensible to the characteristics of the 
test system in vitro even though, probably because of its poor if not null capacity to 
penetrate the cell membranes and to get into the cell [29] the overall pseudo-anti-
metastatic effects are maintained. In particular, the overall study, and particularly that 
on the gene expression of the cells exposed to NAMI-A, supports the published data 
that showed its capacity to reduce the ability of the tumour cell to metastasize without 
any loss of its capacity to grow, reinforcing the hypothesis that this drug targets the 
ability of the cancer cell to positively interact with the tumour microenvironment and 
with the signals that support its metastatic ability. 
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6. LEGEND TO FIGURES 
 
Figure 1. Influence of the co-culture with epithelial colon cells HCEC and with 
hepatocytes IHH on the HCT-116 cell response to NAMI-A. HCT-116 cells were 
sown on a monolayer of HCEC or of IHH and treated with 100 M NAMI-A for 72 
h. At the end the fluorescence associated to cells (H T-116 stained with Fast DiI 
ex/em = 544/580, HCEC and IHH stained with Calcein AM ex/em = 485/520) 
was measured with a fluorimeter. Data are the variations of the percentage ratio 
calculated respect the relevant controls. Tukey-Kramer post-test: ** p<0.01 vs 
monoculture; ° p<0.05 vs NAMI-A untreated HCT-116. 
 
Figure 2. Gene expression variation of HCT-116 exposed to HCEC-CM and IHH-
CM (A), or treated with NAMI-A (B). HCT-116 cells were exposed to HCEC-CM 
and IHH-CM for 24 h (A), or treated with 10 M NAMI-A for 1 h or 24 h (B). Total 
RNA was isolated, reverse transcripted and the levels of the genes were detected 
by qRT-PCR. Data are given as mean  S.D. of the percentage ratio 
treated/untreated. Unpaired t-test: * p<0.05, ** p<0.01, *** p<0.001 vs relevant 
controls. 
 
Figure 3. IHH-CM stimulates the migration of HCT-116 cells. HCT-116 cells were 
exposed to the medium conditioned by hepatocytes (IHH-CM) or not (IHH-M) for 
48 h after drawing a scratch in the cell monolayer. CTRL represents the controls at 
time = 0, right after the drawing of the scratch. 
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Figure 4. NAMI-A effects on HCT-116 cell migration stimulated by IHH-CM. HCT-
116 cells were treated with 1, 10, and 100 M NAMI-A in IHH-M or IHH-CM for 48 
h after drawing a scratch in the cell monolayer. 
 
Figure 5. Modulation of VEGF, MCP-1 and of their combination of HCT-116 cell 
migration. HCT-116 cells were treated with 0.9, 1.8, and 3.6 ng/ml VEGF, 0.07, 
0.7, and 7 ng/ml MCP-1 or with their combination for 48 h after drawing a scratch 
in the cell monolayer. 
 
Figure 6. NAMI-A treatment affects the HCT-116 cell migration induced by 
VEGF, MCP-1 and by their combination. HCT-116 cell were treated with 1, and 
100 M NAMI-A and contemporary with 3.6 ng/ml VEGF, 0.7 ng/ml MCP-1 or with 
their combination for 48 h after drawing a scratch in the cell monolayer. 
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Table 2. Expression levels of cytokines, chemokines and growth factors 
detected in IHH unconditioned (IHH-M) and conditioned (IHH-CM) media 
  Concentration [pg/ml] 
  IHH-M IHH-CM 
Pro-inflammatory cytokines IFN- - 8.50  0.94*** 
 IL-1 0.09  0.01 0.35  0.02** 
 IL-9 1.50 0.08 3.00  0.09*** 
 IL-8 - 150.00  9.40*** 
 IL-12 p70 - 78.00  4.88*** 
 IL-5 0.06  0.01 0.10  0.01* 
 TNF- 2.20  0.01 4.80  0.56** 
 IL-15 32.00  1.00 48.00  1.41*** 
 IL-17A 16.00  1.00 17.00 0.09 
    
Anti-inflammatory cytokines IL-1ra - 9.00  0.70*** 
 IL-4 0.05  0.03 0.22  0.01** 
 IL-10 4.00  0.01 12.00  0.71*** 
 IL-13 0.12  0.01 0.68  0.05*** 
    
Cytokines with dual role IL-6 - 56.00  3.50*** 
 IL-2 10.50  0.10 9.00  0.62 
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Chemokines Eotaxin 5.90  0.01 4.50  0.16** 
 IP-10 2.30  0.01 13.00  0.04*** 
 RANTES 11.00  0.10 12.00  0.38** 
 MIP-1 0.34  0.01 0.50  0.01** 
 MIP-1 1.90  0.06 2.20  0.06* 
 MCP-1 - 700.00  18.00*** 
    
Growth factors b-FGF 14.00  1.00 20.00  1.11** 
 IL-7 0.01  0.01 0.90  0.12*** 
 GM-CSF 140.00  3.00 160.00  4.60* 
 G-CSF 4.00  0.50 11.00  1.38** 
 PDGFbb 2.40  0.13 4.80 0.27*** 
 VEGF - 1600.00  84.00*** 
CM was simultaneously screened for determining the cytokines concentration by interpolation on 
properly generated standard curves. All measurements were performed in triplicate. Data are reported 
as meansSD. * p-value<0.05; ** p-value<0.01; *** p-value<0.001 IHH-CM versus IHH-M.
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Fig. 1 
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Fig. 2 
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Fig. 3
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Fig. 4 
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Fig. 5 
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Fig. 6 
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Graphical abstract 
 
Graphical abstract (synopsis) 
 
Healthy epithelial colon cells and hepatocyte release soluble factors thus promoting the 
transcription of genes of the tumour cells involved in growth, invasion and migration. 
NAMI-A (imidazolium trans-imidazoledimethylsulphoxidetetrachloro ruthenate) 
inhibits the transcription of the same genes and the migration process itself, targeting 
the interactions between cancer cells and the microenvironment. 
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Highlights 
 
 Healthy epithelial colon cells influence the growth of colorectal cancer cells. 
 Soluble factors from the healthy microenvironment cells modulate gene expression. 
 The drug NAMI-A is imidazolium trans-imidazoledimethylsulfoxidetetrachloro 
ruthenate. 
 NAMI-A counteracts the effects of the microenvironment on gene expression. 
 Gene expression control by NAMI-A supports its inhibition of tumour cell migration. 
